Web4 feb. 2024 · Titled, The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A … WebRegister disputes available. You could now file disputes, attach supporting documents, and retrieve literature for submitted disputes available!
Global Urology Implants and Devices Market Outlook - Expert …
Web23 jul. 2015 · An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device. J Endourol. 2024 Jan;37(1):74-79. doi: 10.1089/end.2024.0226. Epub 2024 Oct 3. Web18 nov. 2024 · The innovative procedure was performed by urologist Dr. Christopher Hollowell. November 18, 2024 – Northwest Medical Center is proud to announce it is the first hospital in Florida to offer a procedure which uses new a temporarily implanted device – the iTind, developed by Olympus Medical Systems – to treat benign prostatic … thule supporter
iTIND: the second-generation temporary implantable nitinol …
Web10 jan. 2024 · device group only: Masking: None (Open Label) Primary Purpose: Treatment: Official Title: One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-tate Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH) Actual Study Start Date : February 18, 2024 Web1 jul. 2024 · A self-expanding, temporary nitinol device was placed for 5-7 days and an 18F Foley catheter was inserted and removed for the iTind and sham group, … Web16 dec. 2024 · This was the first prospective trial that validated the efficacy and safety of iTIND. Amparore D, Fiori C, Valerio M, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2024. thule supporter baby